Skip to content

The Role of Inflammation in AMD and Related Disorders

In Vivo Visualization of Active Macrophages and Retinal Pigment Epithelium (RPE) Damage in Age Related Macular Degeneration (AMD) & Related Conditions

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02588378
Enrollment
200
Registered
2015-10-27
Start date
2015-04-30
Completion date
2020-05-31
Last updated
2019-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Related Macular Degeneration

Brief summary

This prospective, non-therapeutic study will compare the relative utility of multiple ocular imaging modalities in the detection of the cellular immune response in patients with AMD and related disorders.

Interventions

PROCEDUREmulti-modal cSLO imaging

Sponsors

Unity Health Toronto
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

STUDY EYE Any tentative clinical diagnosis of the following: 1. Early dry AMD (drusen) with clinical suspicion of CNV 2. Late dry AMD (GA) with clinical suspicion of CNV 3. Reticular Pseudodrusen with clinical suspicion of CNV 4. Polypoidal choroidal vasculopathy 5. Retinal Angiomatous Proliferation 6. Central Serous Retinopathy 7. RPE detachment 8. Conversion to wet AMD (CNV) 9. Decade matched controls Inclusion Criteria CONTROL EYE * Subjects \> 18 years of age * Best corrected visual acuity (BCVA) of 20/32 or better

Exclusion criteria

STUDY/CONTROL EYE: * Patients not able to provide consent for the study. * Patients with a poor view of the fundus due to cataract or vitreous hemorrhage. * Patients \< 18 years of age * Patients with known allergy to angiographic dye * Patients with any concurrent unrelated eye diagnosis that would interfere with image acquisition or interpretation (eg advanced diabetic retinopathy, vascular occlusion, uveitis, or others).

Design outcomes

Primary

MeasureTime frameDescription
Visualization of RPE damage and presumptive immune cells8 monthsQualitative

Countries

Canada

Contacts

Primary ContactShelley Boyd, MD
BoydS@smh.ca416-864-6060

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026